| Name | Title | Contact Details |
|---|
ERMI is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mark Products is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medpricer empowers industry-leading sourcing teams To help you with the continued pressure to optimize healthcare costs, our expert team and best-in-class technology triples your internal sourcing capacity and helps you cut purchased services expenses by an average of 24% without costing you a dime. You lead – We empower You retain the control of your goals and decisions. With the Medpricer methodology and $2.7 billion of Purchased Services sourcing experience, you extend your sourcing capability upfront and establish a best-in-class infrastructure to drive ongoing success in the future. Process more than you ever imagined We discover and optimize every Purchased Service category in your organization. Built on a time-tested methodology, our industry-leading custom contracting platform helps organizations consolidate spend data and manage negotiations more. Your GPO can`t help you like we can We give your team the expertise and flexibility of a consultant with the scalability of a GPO. Access our vendor-paid, independent custom contracting system to secure the right terms at the right price for all of your 400+ Purchased Service categories.
Cytrellis is a medical technology company dedicated to the development and commercialization of first-in-class aesthetic devices which emphasize safety, efficacy, and improved quality of life for our patients. Cytrellis` first product, the ellacor® System with Micro-Coring™ Technology, is indicated for use by medical professionals for the treatment of moderate to severe wrinkles in the mid to lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV. Ellacor provides aesthetic practitioners with an unprecedented ability to improve age-related changes in skin and to help restore youthful beauty.
Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe